Kristina Hooper, a strategist at Invesco, breaks down Nvidia's earnings and predicts how Friday's jobs numbers could affect the Fed rate cut decision this month
Kristina Hooper, a strategist at Invesco, breaks down Nvidia's earnings and predicts how Friday's jobs numbers could affect the Fed rate cut decision this month
Kristina Hooper, a strategist at Invesco, breaks down Nvidia's earnings and predicts how Friday's jobs numbers could affect the Fed rate cut decision this month
The Federal Reserve is expected to cut rates in September. Kristina Hooper, a strategist at Invesco, breaks down what the market's reaction will be
Cows at three California dairy farms have been placed under quarantine after testing positive for avian influenza, commonly known as bird flu
The Federal Reserve is expected to cut rates in September. Kristina Hooper, a strategist at Invesco, breaks down what the market's reaction will be
Jeff Weniger from WisdomTree, the No. 2 investor in Japan ETFs in the U.S., believes the yen carry-trade fallout is over
What happens if the Bank of Japan raises interest rates and the yen carry-trade fallout continues? Jeff Weniger of WisdomTree breaks it down
Current Disney CEO Bob Iger is set to step down from his role — for the second time — in 2026.
Jeff Weniger of WisdomTree predicts four consecutive quarter-point rate cuts from The Federal Reserve and Chairman Jerome Powell this year
Jeff Weniger of WisdomTree breaks down what it would mean for investors if Harris raised the corporate tax rate to 28% and enforced a food price gouging ban
Jeff Weniger of WisdomTree breaks down what it would mean for investors if Harris raised the corporate tax rate to 28% and enforced a food price-gouging ban
The Federal Reserve chairman is set to speak Friday as investors eagerly await interest rate cuts
John Rossman, who played a pivotal role in leading the launch of Amazon’s Marketplace, says Starbucks should ask itself 'What Sucks?'
The U.S. Department of Health and Human Services announced Thursday the lowered prices of the first 10 prescription drugs that underwent Medicare negotiations
The sweet-and-salty deal is set to enhance M&M maker Mars’ global snacking portfolio and combine two well-established companies with complementary brands
Carol Schleif of BMO Family Office breaks down what investors can learn about consumer spending from Starbucks' CEO shakeup and Home Depot's sales concerns
Carol Schleif of BMO Family Office breaks down what investors can learn about consumer spending from Starbucks' CEO shakeup and Home Depot's sales concerns
The company's second-quarter revenue fell 30% from a year prior
Microsoft said Delta "likely refused" its help because its worst hit IT systems is serviced by other providers

Tim Urbanowicz, Head of Research and Investment Strategy at Innovator ETFs, discusses how to spot opportunities amid a turbulent stock market
Tim Urbanowicz, Head of Research and Investment Strategy at Innovator ETFs, breaks down what the stock market turbulence means for investors
Warren Buffett's $234.6 billion investment in T-bills has eclipsed the Federal Reserve's $195.3 billion
The medication, tirzepatide, is sold by the company in the United States as Mounjaro for diabetes and Zepbound for weight loss
Oreos and Chips Ahoy are getting too expensive for shoppers and it’s hurting sales at Mondelez International